Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1995-10-30
1998-06-09
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
A61K 31225
Patent
active
057634882
ABSTRACT:
The present invention relates to the use of butyrate esters of threitol, alone or in combination with other agents, in pharmaceutical compositions and methods for increasing fetal hemoglobin and gamma globin in a patient. These methods are particularly useful in treating .beta.-hemoglobinopathies, such as sickle cell syndromes and .beta.-thalassemia syndromes. Compositions comprising butyrate esters of threitol, alone or in combination antiproliferative and differentiating agents are also useful in methods for inducing cell differentiation in malignant cells. These methods are useful in treating cancer, particularly the tetrabutyrate ester.
REFERENCES:
patent: 5569675 (1996-10-01), Rephaeli et al.
Abraham Nudelman et al., "Novel Anticancer Prodrugs of Butyric Acid," J. Med. Chem., vol. 35, pp. 694-704 (1992).
Harold L. Newmark and Charles W. Young, "Butyrate and Phenylacetate as Differentiating Agents: Practical Problems and Opportunities," J. Cell. Biochem., vol. 22, pp. 247-253 (1995).
Zi-Xing Chen and Theodore R. Breitman, "Tributyrin: A Prodrug of Butyric Acid for Potential Clinical Applicaton in Differentiation Therapy," Cancer Research, vol. 54, pp. 3494-3499 (1994).
Antonius A. Miller et al., "Clinical Pharmacology of Sodium Butyrate in Patients with Acute Leukemia," Eur. J. Clin. Oncol., vol. 23, No. 9, pp. 1283-1287 (1987).
Anne F. Collins et al., "Oral Sodium Phenylbutyrate Therapy in Homozygous .beta.-Thalassemia: A Clinical Trial," Blood, vol. 85, pp. 43-49 (1995).
Charles Chany and Italina Cerutti, "Antitumour Effect of Arginine Butyrate in Conjunction with Corynebacterium parvum and Interferon," Int. J. Cancer, vol. 30, pp. 489-493 (1982).
Philippe Pouillart el al., "Pharmacokinetic Studies of N-Butyric Acid Mono-and Polyesters Derived from Monosaccharaides," J. Pharm. Sci., vol. 81, No. 3, pp. 241-244 (1992).
Michiro Otaka et al., "Antibody-Mediated Targeting of Differentiation Inducers to Tumor Cells: Inhibition of Colonic Cancer Cell Growth In Vitro and In Vivo, A Preliminary Note," Biochem. Biophy. Res. Comm., vol. 158, No. 1, pp. 202-208 (1989).
Abraham Novogrodsky et al., "Effect of Polar Organic Compounds on Leukemic Cells: Butyrate-Induced Partial Remission of Acute Myelogenous Leukemia in a Child," Cancer, vol. 51, No. 1, pp. 9-14, (1983).
O. C. Velazquez et al., "Tutyrate and the Coloncyte: Implications for Neoplasia," Dig. Dis. Sci., vol. 41, pp. 727-739 (1996).
A. Hague et al., "Apoptosis in Colorectal Tumour Cells: Induction by the Short Chain Fatty Acids Butyrate, Propionate and Acetate and by the Bile Salt Deoxycholate," Int. J. Cancer, vol. 60, pp. 400-406 (1995).
K. N. Prasad, "Butyric Acid: A Small Fatty Acid with Diverse Biological Functions," Life Sci., vol. 27, pp. 1351-1358 (1980).
Newmark et al., "Butyrate as a Differentiating Agent: Pharmacokinetics, Analogues and Current Status"; Cancer Letters, vol. 78, pp. 1-5 (1994).
Pouillart el al., "Butyric Monosaccharide Ester-Induced Cell Differentiation And Anti-Tumor Activity In Mice. Importance Of Their Prolonged Biological Effect For Clinical Applications in Cancer Therapy"; Int. J. Cancer, vol. 49, pp. 89-95 (1991).
Bemis Guy W.
Chaturvedi Pravin R.
Goldberg Jerome D.
Haley, Jr. James F.
Marks Andrew S.
Vertex Pharmaceuticals Incorporated
LandOfFree
Methods and compositions using butyrate esters of threitol does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions using butyrate esters of threitol, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions using butyrate esters of threitol will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2199817